In the BioHarmony Drug Report Database
Serdexmethylphenidate
Azstarys (serdexmethylphenidate) is a small molecule pharmaceutical. Serdexmethylphenidate was first approved as Azstarys on 2021-05-07. It is used to treat attention deficit disorder with hyperactivity in the USA. Azstarys’s patents are valid until 2037-12-09 (FDA).
Trade Name
|
Azstarys |
|---|---|
Common Name
|
serdexmethylphenidate |
ChEMBL ID
|
CHEMBL4301162 |
Indication
|
attention deficit disorder with hyperactivity |
Drug Class
|
Image (chem structure or protein)